Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
- 30 November 2005
- journal article
- review article
- Published by Elsevier
- Vol. 26 (11) , 565-571
- https://doi.org/10.1016/j.it.2005.08.014
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- Combination of Gene Delivery and DNA Vaccination to Protect from and Reverse Th1 Autoimmune Disease via Deviation to the Th2 PathwayImmunity, 2001
- TNF-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overviewJournal of Neuroimmunology, 1997
- Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic proteinNature, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- The T Lymphocyte in Experimental Allergic EncephalomyelitisAnnual Review of Immunology, 1990
- Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantroneClinical Immunology and Immunopathology, 1987
- Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition.The Journal of Experimental Medicine, 1985
- Suppression of experimental allergic encephalomyelitis by mitoxantroneClinical Immunology and Immunopathology, 1985
- Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymerClinical Immunology and Immunopathology, 1974